A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer
| Autor: | J. Shultz, Nancy E. Kemeny, R. Isaacs, Charles D. Blanke, Malcolm J. Moore, John Cox, Daniel G. Haller, B. Kasimis, M. Modiano, Richard L. Schilsky, D. Carlin, J. Fleagle, L. Hammershaimb |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Randomization Adolescent medicine.medical_treatment Leucovorin Placebo Gastroenterology law.invention Double-Blind Method Randomized controlled trial law Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Survival rate Aged Aged 80 and over Chemotherapy business.industry Hematology Middle Aged Surgery Survival Rate Regimen Trimetrexate Oncology Fluorouracil Disease Progression Quality of Life Female Colorectal Neoplasms business medicine.drug |
| Zdroj: | Annals of Oncology. 13:87-91 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdf043 |
| Popis: | Background Trimetrexate (TMTX) biochemically modulates 5-fluorouracil (5-FU) and leucovorin (LCV). Two phase II trials demonstrated promising activity for TMTX/5-FU/LCV in patients with untreated advanced colorectal cancer (ACC). This trial was designed to demonstrate the safety and efficacy of TMTX/5-FU/LCV as first-line treatment in ACC. Patients and methods Eligible patients with ACC were randomized in double-blind fashion to receive placebo or TMTX (110 mg/m2) intravenously (i.v.) followed 24 h later by i.v. LCV 200 mg/m2, and 5-FU 500 mg/m2 plus oral LCV rescue. Both schedules were given weekly for 6 weeks every 8 weeks. Patients were evaluated for progression-free survival (PFS), overall survival (OS), tumor response, quality of life (QoL) and toxicity. Results A total of 382 eligible patients were randomized. Significant toxicities were noted more frequently with TMTX/5-FU/LCV. Diarrhea was the most common grade 3 or 4 side-effect (41% and 28% on the TMTX and placebo arms, respectively). QoL scores and response rates did not differ between treatment arms. PFS was 5.3 months and 4.4 months in the TMTX and placebo arms, respectively (P = 0.77; Wilcoxon). OS was 15.8 months and 16.8 months, respectively (P = 0.73; Wilcoxon). Conclusions The addition of TMTX to a weekly regimen of 5-FU/LCV worsened grade 3 or 4 diarrhea. The inclusion of TMTX did not yield any significant improvements in response rate, PFS or OS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|